What happened
A bispecific antibody Tab1 targeting PD-L1 and VEGF demonstrates enhanced antitumor efficacy in preclinical models
SourceElsevier BVpublicationBiotech
A bispecific antibody Tab1 targeting PD-L1 and VEGF demonstrates enhanced antitumor efficacy in preclinical models
Publication signal: A bispecific antibody Tab1 targeting PD-L1 and VEGF demonstrates enhanced antitumor efficacy in preclinical models
Factual summary
Why it matters
Recent source-backed research output for AISci Stage A browsing.
SourceElsevier BVLimitations
AISci rank score does not assess scientific quality or citation impact.
SourceElsevier BVLinked output
A bispecific antibody Tab1 targeting PD-L1 and VEGF demonstrates enhanced antitumor efficacy in preclinical modelspaperPeople
No reviewed person relationship is attached to this event.
Organizations
No reviewed organization relationship is attached to this event.
Topics
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
A bispecific antibody Tab1 targeting PD-L1 and VEGF demonstrates enhanced antitumor efficacy in preclinical models
A bispecific antibody Tab1 targeting PD-L1 and VEGF demonstrates enhanced antitumor efficacy in preclinical models
Protein and Drug Design
Controlled AISci Stage A topic for Protein and Drug Design.
Timeline
- publicationA bispecific antibody Tab1 targeting PD-L1 and VEGF demonstrates enhanced antitumor efficacy in preclinical models